Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase

International Immunopharmacology

Volumn 10, Issue 4, 2010, Pages 467-473

  Chopra, Puneet ^a   Kulkarni, Onkar ^a   Gupta, Shashank ^a   Bajpai, Malini ^a   Kanoje, Vijay ^a   Banerjee, Manish ^a   Bansal, Vimal ^a   Visaga, Senthil ^a   Chatterjee, Mou ^a   Chaira, Tridib ^a   Shirumalla, Raj Kumar ^a   Verma, Ashwani Kumar ^a   Dastidar, Sunanda G ^a   Sharma, Geeta ^a   Ray, Abhijit ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Arthritis; Collagen induced arthritis; Inflammation; Interleukin; Kinases; MAP kinases; p38; Tumor necrosis factor

Indexed keywords

5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; [2 (HEXAHYDRO CYCLOPENTA[C]PYRROL 2 YLAMINO) 8 METHYL 6 2 TOLYL 8H PYRIDO[2,3 D]PYRIMIDINE 7 ONE]; AW 814141; CARRAGEENAN; DEXAMETHASONE; DORAMAPIMOD; INDOMETACIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENDOTOXEMIA; ENZYME ACTIVITY; FEMALE; IC 50; INFLAMMATION; MALE; MOUSE; NONHUMAN; PAW EDEMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CELL DEATH; COLLAGEN; CYTOKINES; EDEMA; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; KINETICS; LIPOPOLYSACCHARIDES; MALE; MICE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINES; RATS; RATS, WISTAR; SUBSTRATE SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949489123     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.01.007     Document Type: Article

References (35)

1. Carteron N.L. Cytokines in rheumatoid arthritis: trials and tribulations. Mol Med Today 6 (2000) 315-323
2. Mease P.J., and Antoni C.E. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 64 (2005) 78-82
3. Wollheim F.A. TNF inhibition as therapy for rheumatoid arthritis. Expert Opin Investig Drugs 11 (2002) 947-953
4. Fleischmann R.M., Iqbal I., and Stern R.L. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 3 (2004) 391-403
5. Pearson G., Robinson F., Beers G.T., Xu B.E., Karandikar M., Berman K., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22 (2001) 153-183
6. Lee J.C., Laydon J.T., Mcdonnell P.C., Gallagher T.F., Kumar S., Green D., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
7. Jiang Y., Chen C., Li Z., Guo W., Gegner J.A., Lin S., et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 271 (1996) 17920-17926
8. Li Z., Jiang Y., Ulevitch R.J., and Han J. The primary structure of p38γ: a new member of p38 group of map kinases. Biochem Biophys Res Commun 228 (1996) 334-340
9. Kumar S., Boehm J., and Lee J.C. p38 map kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2 (2003) 717-726
10. Haddad J.J. Vx-745 Vertex pharmaceuticals. Curr Opin Investig Drugs 2 (2001) 1070-1076
11. Haddad E.B., Birrell M., Mccluskie K., Ling A., Webber S.E., Foster M.L., et al. Role of p38 map kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol 132 (2001) 1715-1724
12. Jackson J.R., Bolognese B., Hillegass L., Kassis S., Adams J., Griswold D.E., et al. Pharmacological effects of SB-220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 284 (1998) 687-692
13. Nikas S.N., and Drosos A.A. Scio-469 Scios inc. Curr Opin Investig Drugs 5 (2004) 1205-1212
14. Branger J., Van den blink B., Weijer S., Madwed J., Bos C.L., Gupta A., et al. Anti- inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168 (2002) 4070-4077
15. Treu M., Jordis U., and Lee V.J. An improved synthesis of 5-(2, 6- dichlorophenyl)-2-(phenyl-thio)- 6 h-pyrimidol [1, 6-blpyridazin-6-one (Vx-745)]. Molecules 6 (2001) 959-963
16. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A.G., Hickey E., et al. Pyrazole urea-based inhibitors of p38 map kinase: from lead compound to clinical candidate. J Med Chem 45 (2002) 2994-3008
17. Mccauley T.J., Stanaitis M.L., Savage M.D., Onken J., and Millis S.Z. Iq™ technology: development of a universal, homogeneous method for high-throughput screening of kinase and phosphatase activity. J Assoc Lab Autom 8 (2003) 36-40
18. Patricelli M.P., Szardenings A.K., Liyanage M., Nomanbhoy T.K., Wu M., Weissig H., et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46 (2007) 350-358
19. Bruno S., Ardelt B., Skierski J.S., Traganos F., and Darzynkiewicz Z. Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res 52 (1992) 470-473
20. Weiss T., Shalit I., Blau H., Werber S., Halperin D., Levitov A., et al. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother 48 (2004) 1974-1982
21. Underwood D.C., Osborn R.R., Kotzer C.J., Adams J.L., Lee J.C., Webb E.F., et al. SB239063, a potent p38 map kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil Infiltration, and persistence. J Pharmacol Exp Ther 293 (2000) 281-288
22. Chopra P., Bajpai M., Dastidar S.G., and Ray A. Development of a cell death-based method for the screening of nuclear factor-kappaB inhibitors. J Immunol Methods 335 (2008) 126-131
23. Phyllis EW, Stacie AD. Models of inflammation: carrageenan-induced paw edema in the rat. in: Current protocols in pharmacology. pp 5.4.1-5.4.3, John Willie & Sons, inc.
24. Campo G.M., Avenoso A., Campo S., Ferlazzo A.M., Altavilla D., and Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arth Res Ther 5 (2003) 122-131
25. Hale K.K., Trollinger D., Rihanek M., and Manthey C.L. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol 162 (1999) 4246-4252
26. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79 (1999) 143-180
27. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl. J Med 344 (2001) 907-916
28. Li Q., and Verma I.M. NF-kappa B regulation in the immune system. Nat Rev Immunol 2 (2002) 725
29. Sekut L., Menius Jr. J.A., Brackeen M.F., and Connolly K.M. Evaluation of the significance of elevated levels of systemic and localized tumor necrosis factor in different animal models of inflammation. J Lab Clin Med 124 (1994) 813-820
30. Nishikori T., Irie K., Suganuma T., Ozaki M., and Yoshioka T. Anti-inflammatory potency of FR167653, a p38 mitogen-activated protein kinase inhibitor, in mouse models of acute inflammation. Eur J Pharmacol 451 (2002) 327-333
31. Suleyman H., and Buyukokuroglu M.E. The effects of newly synthesized pyrazole derivatives on formaldehyde-carrageenan- and dextran-induced acute paw edema in rats. Biol Pharm Bull 24 (2001) 1133-1136
32. Stuart J.M., Townes A.S., and Kang A.H. Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. J Clin Invest 69 (1982) 673-683
33. Alonzi T., Fattori E., Lazzaro D., Costa P., Probert L., Kollias G., et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187 (1998) 461-468
34. Campbell I.K., O'donnell K., Lawlor K.E., and Wicks I.P. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 107 (2001) 1519-1527
35. Williams R.O., Marinova-mutafchieva L., Feldmann M., and Maini R.N. Evaluation of TNF- alpha and Il-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-cd4 therapy. J Immunol 165 (2000) 7240-7245